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Summary
Background Clinical prognostic groupings for localised prostate cancers are imprecise, with 30–50% of patients 
recurring after image-guided radiotherapy or radical prostatectomy. We aimed to test combined genomic and 
microenvironmental indices in prostate cancer to improve risk stratiﬁ cation and complement clinical prognostic factors.
Methods We used DNA-based indices alone or in combination with intra-prostatic hypoxia measurements to develop 
four prognostic indices in 126 low-risk to intermediate-risk patients (Toronto cohort) who will receive image-guided 
radiotherapy. We validated these indices in two independent cohorts of 154 (Memorial Sloan Kettering Cancer Center 
cohort [MSKCC] cohort) and 117 (Cambridge cohort) radical prostatectomy specimens from low-risk to high-risk 
patients. We applied unsupervised and supervised machine learning techniques to the copy-number proﬁ les of 
126 pre-image-guided radiotherapy diagnostic biopsies to develop prognostic signatures. Our primary endpoint was 
the development of a set of prognostic measures capable of stratifying patients for risk of biochemical relapse 5 years 
after primary treatment.
Findings Biochemical relapse was associated with indices of tumour hypoxia, genomic instability, and genomic subtypes 
based on multivariate analyses. We identiﬁ ed four genomic subtypes for prostate cancer, which had diﬀ erent 5-year 
biochemical relapse-free survival. Genomic instability is prognostic for relapse in both image-guided radiotherapy 
(multivariate analysis hazard ratio [HR] 4·5 [95% CI 2·1–9·8]; p=0·00013; area under the receiver operator curve [AUC] 
0·70 [95% CI 0·65–0·76]) and radical prostatectomy (4·0 [1·6–9·7]; p=0·0024; AUC 0·57 [0·52–0·61]) patients with 
prostate cancer, and its eﬀ ect is magniﬁ ed by intratumoral hypoxia (3·8 [1·2–12]; p=0·019; AUC 0·67 [0·61–0·73]). A 
novel 100-loci DNA signature accurately classiﬁ ed treatment outcome in the MSKCC low-risk to intermediate-risk 
cohort (multivariate analysis HR 6·1 [95% CI 2·0–19]; p=0·0015; AUC 0·74 [95% CI 0·65–0·83]). In the independent 
MSKCC and Cambridge cohorts, this signature identiﬁ ed low-risk to high-risk patients who were most likely to fail 
treatment within 18 months (combined cohorts multivariate analysis HR 2·9 [95% CI 1·4–6·0]; p=0·0039; AUC 0·68 
[95% CI 0·63–0·73]), and was better at predicting biochemical relapse than 23 previously published RNA signatures.
Interpretation This is the ﬁ rst study of cancer outcome to integrate DNA-based and microenvironment-based failure 
indices to predict patient outcome. Patients exhibiting these aggressive features after biopsy should be entered into 
treatment intensiﬁ cation trials.
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Introduction
Every year, almost 900 000 men worldwide are diagnosed 
with prostate cancer, and 250 000 men die annually from 
the disease.1 Most cases are localised cancers, which are 
stratiﬁ ed into low-risk, intermediate-risk and high-risk 
groups on the basis of their prostate cancer-speciﬁ c 
mortality.2 These clinical prognostic groups are based on 
pretreatment PSA (PSA), biopsy-based pathological 
Gleason scores, and TNM staging descriptors, such as 
the National Comprehensive Cancer Network 
classiﬁ cation system.3
Low-risk patients (ie, those with Gleason scores ≤6, 
PSA concentrations <10 ng/mL, or T1–T2a) can be 
oﬀ ered active surveillance, sparing them the toxic eﬀ ects 
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of treatment. By contrast, patients with intermediate risk 
(Gleason scores of 7, PSA concentrations of 10–20 ng/mL, 
or T2b-c) and high risk or locally advanced (Gleason 
scores ≥8, prostate speciﬁ c antigen concentrations 
≥20 ng/mL, or T3/4) prostate cancer often undergo 
radical prostatectomy or image-guided radiotherapy, or 
receive intensiﬁ ed regimens adding adjuvant androgen 
deprivation therapy or novel systemic drugs to prevent 
progression to metastatic castration-resistant prostate 
cancer. However, use of treatment intensiﬁ cation for 
individual patients is imprecise: 30–50% of patients have 
biochemical relapse despite radical prostatectomy or 
image-guided radiotherapy.4,5 Furthermore, nearly 20% 
of intermediate-risk patients have biochemical failure 
within 18 months of primary local therapy (ie, rapid 
failure). Such failure might be be due to pre-existing 
occult metastatic disease, because rapid biochemical 
failure is a surrogate for prostate-cancer-speciﬁ c 
mortality.6,7 The basis of this interpatient clinical hetero-
geneity has not been clinically resolved.8,9
A signature to classify patients as potential responders 
or non-responders to local therapy would have great 
clinical use if it was treatment-independent (ie, eﬀ ective 
both for patients undergoing radical prostatectomy or 
image-guided radiotherapy) and could be done on initial 
diagnostic biopsies. Such a signature could triage 
patients at greatest risk of failure into clinical trials for 
treatment intensiﬁ cation and justify potential added toxic 
eﬀ ects.7,10 DNA copy number alterations in PTEN, 
NKX3-1, MYC, and STAR are associated with adverse 
prognosis,11,12 and RNA-based gene signatures might 
diﬀ erentiate indolent and non-indolent, lethal prostate 
cancer.13-15 TMPRSS2–ERG fusion status does not predict 
prognosis after radical prostatectomy or image-guided 
radiotherapy.16,17 Importantly, tumour cells exist within a 
heterogeneous tumour microenvironment with dynamic 
gradients of hypoxia that have been linked to metastatic 
potential.9,18 Indeed, patients with prostate cancer with 
hypoxic tumours rapidly fail treatment (eg, within 
2 years) after radical prostatectomy or image-guided 
radiotherapy.19,20 Up to now, the interplay of genomic 
instability and tumour microenvironment in modulation 
of treatment outcome has been unexplored. We therefore 
aimed to develop clinically relevant prognostic indices, 
with use of integrated tumour DNA and 
microenvironmental indices, to robustly predict patient 
outcome.
Methods
Study design and patients
Our training (Toronto) cohort for generation of biopsy-
based signatures consisted of pre-image-guided 
radiotherapy, clinically-staged patients with prostate 
cancer, who were classiﬁ ed as low-risk or intermediate-
risk on the basis of National Comprehensive Cancer 
Network guidelines (appendix).3 To validate our ﬁ ndings, 
we used copy number alteration proﬁ les from two 
cohorts of clinically staged (ie, similar to pre-image-
guided radiotherapy patients) low-risk to high-risk radical 
prostatectomy patients (Memorial Sloan Kettering 
Cancer Center cohort [MSKCC] and Cambridge cohorts; 
appendix).8 The radical prostatectomy cohorts were 
considered both separately and together. We deﬁ ned copy 
number alteration proﬁ les relative to the hg19 human 
genome build.
DNA was extracted from pretreatment biopsies that 
consisted of at least 70% tumour cells as estimated by a 
pathologist (TvdK), and a custom array was used to 
detect copy number alterations.12 Intraglandular 
measure ments of partial oxygen pressure were taken 
before radiotherapy with an ultrasound-guided trans-
rectal needle piezoelectrode.20
We developed four prognostic indices and validated 
them for prediction of biochemical relapse (appendix). 
The appendix provides an overview of our approach to 
develop treatment-independent, integrated prognostic 
indices. First, we identiﬁ ed unique genomic subtypes 
with use of unsupervised hierarchical clustering. Second, 
we used the percentage of a patient’s genome harbouring 
copy number alterations (percent genome alteration) as a 
surrogate for genomic instability, and assessed this 
proportion together with tumour hypoxia. Third, we 
undertook supervised machine learning with a random 
forest21 to develop a statistical model, resulting in a DNA 
signature, which classiﬁ ed patients at risk of biochemical 
relapse on the basis of their copy-number proﬁ les. We 
compared the resulting signature with published RNA-
based signatures.
Statistical analysis
Our main aim was the development of a set of prognostic 
measures capable of stratifying patients for risk of 
biochemical relapse (deﬁ ned as an increase in 
concentration of prostate-speciﬁ c antigen of at least 
2 ng/mL above the post-radiation nadir value for image-
guided radiotherapy patients and, for radical 
prostatectomy patients, as two consecutive concentration 
values >0·2 ng/mL or triggered salvage radiotherapy22,23) 
5 years after primary treatment. Our secondary aim was 
the status at 18 months. We assessed prognosis for 
biochemical relapse by the area under the receiver 
operator curve (AUC), C-index analysis, and Cox 
proportional hazard regression models. We modelled 
indices with univariate and multivariate analyses, with 
multivariate analyses correcting for Gleason score and 
pre-treatment concentrations of PSA (and clinical T 
stage during assessment of high-risk patients; appendix). 
The appendix shows full C-index analyses for each 
biomarker. We used two-sided non-parametric tests to 
compare patient subsets. We applied multiple-testing 
correction with the Benjamini-Hochberg or Bonferroni 
method, as indicated. We did all bioinformatic and 
statistical analyses in the R statistical environment 
(version 3.0.2).
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Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We used information derived from 126 pre-image-
guided radiotherapy biopsies (Toronto cohort) and did 
initial validation with 154 radical prostatectomy 
specimens (MSKCC cohort). We obtained a secondary 
independent cohort of 117 radical prostatectomy 
specimens for further validation of putative biomarkers 
(Cambridge cohort). Clinical characteristics of the 
patients are listed in the appendix (pp 11–12). We 
focused on clinically-matched validation cohorts 
containing low-risk and intermediate-risk patients 
(n=210) who might need treatment intensiﬁ cation 
beyond local therapy alone, but also considered all 
patients with localised disease who might be candidates 
for intensiﬁ cation or de-intensiﬁ cation (full validation 
cohort n=271). 5-year biochemical relapse-free survival 
of the three study cohorts were broadly similar (appendix 
pp 36–39). Pretreatment PSA was prognostic in image-
guided radiotherapy patients, whereas pretreatment 
Gleason score, T category, and PSA were all prognostic 
in the full MSKCC and Cambridge cohorts (table 1).
Our initial analyses showed that Toronto and MSKCC 
cohorts showed extensive genomic heterogeneity, even 
for patients who were low-risk or intermediate-risk, or 
had Gleason scores of 6 or 7 (appendix pp 13, 40–43). The 
most recurrent copy number alterations in either cohort 
were 8p ampliﬁ cations and 8q deletions, in addition to 
deletions of 16q23·2 and 6q15 (harbouring MAF and 
MAP3K7; table 2), which have been noted in aggressive 
tumours.24 We established the frequency of copy number 
alterations for a set of genes putatively prognostic for 
adverse outcomes, selected from our previous studies 
and the literature, in the Toronto image-guided 
radiotherapy biopsies (appendix p 44). Despite low-risk or 
intermediate-risk classiﬁ cation, 76 (60%) of 126 patients 
had copy number alterations in at least two adverse 
prognosis genes. We noted this variability across the 
genome, suggesting that genomically deﬁ ned subtypes 
of prostate cancer might be obtained from biopsies.
Unbiased hierarchical clustering in the Toronto cohort 
(appendix pp 45–46) showed four localised prostate 
cancer subtypes with distinct genomic proﬁ les: subtype 1 
(characterised by gain of chromosome 7), subtype 2 
(deletion of 8p and gain of 8q), subtype 3 (loss of 8p and 
16q), and subtype 4 (so-called quiet genomes due to few 
genomic alterations). Subtypes 2 and 3 share many 
common genetic alterations (504 genes altered in >25% 
of patients in both subtypes), but χ² tests showed eight 
regions that diﬀ ered signiﬁ cantly, including gain of 8q in 
Toronto MSKCC full Cambridge full
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Data for each prognostic clinical variable*
Gleason score
7 vs 5–6 1·0 (0·44–2·4; 0·95) 1·0 (0·44–2·5; 0·92) 3·4 (1·5–8·0; 0·0044) 2·8 (1·2–6·71; 0·019) 6·2 (0·82–47; 0·078) 5·6 (0·74–43; 0·95)
8–9 vs 5–6 NA NA 7·3 (2·9–18; <0·0001) 4·9 (1·8–131; 0·0015) 8·1 (0·85–78; 0·069) 5·7 (0·58–56; 0·14)
PSA (continuous)† 1·2 (1·1–1·3; 0·0012) NA 1·006 (1·003–1·009; 0·00030) NA 1·1 (1·0–1·2; 0·063) NA
T category
T2 vs T1‡ 0·82 (0·39–1·7; 0·60) 0·86 (0·40–1·8; 0·69) NA NA NA NA
T3 vs T1–2‡ NA NA 9·2 (4·1–21; <0·0001) 6·1 (2·6–14; <0·0001) 2·8 (1·0–7·8; 0·50) 3·6 (1·2–11; 0·024)
National Comprehensive Cancer Network classiﬁ cation
Intermediate vs low risk 1·4 (0·43–4·7; 0·57) NA 2·5 (0·80–7·91; 0·12) NA 2·2 (0·28–18; 0·45) NA
High vs low risk NA NA 12·6 (4·3–37; <0·0001) NA 6·9 (0·88–55; 0·66) NA
Data for dichotomised and continuous PGA§
≥7·49 vs <7·49 4·2 (2·0–8·9; 0·00019) 4·5 (2·1–9·8; 0·00013) 4·5 (2·3–8·9; <0·0001) 3·4 (1·6–7·2; 0·0011) 3·8 (1·4–9·9; 0·0075) 3·2 (1·1–9·0; 0·029)
Continuous 1·05 (1·03–1·08; <0·0001) 1·06 (1·03–1·09; 0·00019) 1·08 (1·04–1·13; 0·0098) 1·05 (1·0–1·1; 0·065) 1·09 (1·0–1·2; 0·0020) 1·08 (1·0–1·1; 0·0012)
AUC 0·71 (0·66–0·77) 0·70 (0·65–0·76) 0·49 (0·44–0·54) 0·82 (0·76–0·88) 0·70 (0·63–0·77) 0·71 (0·58–0·73)
C index 0·72 (0·64–0·81) 0·63 (0·60–0·79) 0·60 (0·48–0·72) 0·76 (0·63–0·80) 0·65 (0·50–0·70) 0·72 (0·61–0·84)
Data are hazard ratio (95% CI) or hazard ratio (95% CI; p-value). 5-year biochemical relapse rate was used in the Cox proportional hazard models except for the Cambridge cohort in which 18-month biochemical 
relapse rate was used. IGRT=image-guided radiotherapy. MSKCC=Memorial Sloan Kettering Cancer Center. NA=not applicable. PGA=percentage of genome alteration. AUC=area under the receiver operator 
curve. *Data from Cox proportional hazard models are shown for each prognostic clinical variable in the univariate and multivariate setting for each full cohort. Multivariate models include Gleason score, 
prostate-speciﬁ c antigen, and T category only (National Comprehensive Cancer Network classiﬁ cation is not included). The multivariate models show the covariates and levels used for multivariate analysis of 
biomarkers throughout the study. †PSA is stratiﬁ ed at 10 ng/mL because it fails the proportional hazards assumption. ‡For the Toronto-IGRT cohort, in which there were only low-risk to intermediate-risk 
patients, we compared T2–T1 patients, whereas for the radical prostatectomy cohorts, we compared T3 patients with T1–2 patients. §Data are provided for dichotomised and continuous PGA in each cohort, on 
the basis of Cox proportional hazard models including only the marker of interest (univariate) and models including relevant clinical covariates as shown in the table (multivariate). The AUC and C index are 
provided for the continuous PGA values.
Table 1: Biomarker summary for each prognostic clinical variable and for PGA in each cohort
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subtype 2 and 16q deletion in subtype 3 (appendix p 14). 
All four subtypes were conﬁ rmed in the MSKCC radical 
prostatectomy cohort and were not associated with 
TMPRSS2–ERG fusion, Gleason score, or T category 
(appendix pp 15–17, 47–48).
In a pooled analysis of low-risk and intermediate-risk 
patients (using the Toronto and MSKCC cohorts; 
250 patients), the four genomic subtypes of localised 
prostate cancer had signiﬁ cantly diﬀ erent prognoses, 
even after adjustment for clinical variables (ﬁ gure 1, 
appendix pp 15–19, 43–49). Patients classiﬁ ed as 
subtype 4 had a signiﬁ cantly better prognosis compared 
with those with other subtypes (ﬁ gure 1). Biochemical 
relapse-free survival at 5 years was 58% (95% CI 37–92) 
for subtype 1, 55% (37–81) for subtype 2, 53% (37–78) for 
subtype 3, and 89% (84–94) for subtype 4. Subtype 1 
seems to be characterised by increased relapse after 
3 years rather than increased risk at all times, but larger 
cohorts are needed to clarify this ﬁ nding. These 
subtypes are prognostic for biochemical recurrence by 
18 months (log-rank p value 0·0024, low-risk to 
intermediate-risk cohort), which is associated with 
increased prostate-cancer-speciﬁ c mortality.6,7 Indeed, in 
the Toronto cohort, being subtype 2 was associated with 
signiﬁ cantly worse overall survival than being in 
subtype 4 (HR 4·2 (95% CI 1·2–15; Wald p=0·03; 
appendix p 19).
The excellent prognosis of so-called quiet subtype 4 
suggested that genome-wide instability might be 
prognostic in itself. With the percentage of the genome 
showing a copy number alteration as a proxy for 
genomic instability, we noted interpatient variability in 
percentage of genome alteration ranging from 0–52% in 
the Toronto cohort, to 0–34% in the MSKCC cohort, and 
0–28% in the Cambridge cohort. Percentage of genome 
alteration was independent of Gleason score, T category, 
and PSA in all cohorts (ﬁ gures 2A–C). Indeed, individual 
Gleason score-6 tumours had a higher percentage of 
genome alteration than did some Gleason score 4 + 3 
tumours (ﬁ gure 2A), suggesting that percentage of 
genome alteration reﬁ nes biological description even in 
tumours of mainly pattern 4. As expected, based on 
previous ﬁ ndings, the percentage of genome alteration 
was increased in patients with prognostic CHD1 
deletions (appendix p 50).25
Percentage of genome alteration was strongly 
prognostic, independent of clinical covariates, as 
previously reported.26 Every 1% increase in percentage of 
alteration led to a 5–8% decrease in 5-year biochemical 
relapse-free survival (C-index 0·60–0·72; appendix 
pp 20–21). To classify the likelihood of clinical failure on 
the basis of percentage of genome alteration, we set the 
upper tertile of 7·49% from the Toronto cohort as the 
lower bound threshold, which eﬃ  ciently stratiﬁ ed 
patients who underwent either image-guided radio-
therapy (multivariate analysis HR for biochemical 
relapse 4·5 [95% CI 2·1–9·8]; Wald p=0·00013) or radical 
prostatectomy (eg, pooled radical prostatectomy low-risk 
to intermediate-risk cohort: multivariate analysis HR for 
biochemical relapse 4·0 [1·6–9·7]; Wald p=0·0024; 
ﬁ gure 3A–C). These results are threshold-independent 
(appendix p 51). The HR for the pooled radical 
prostatectomy full (ie, low, intermediate, and high-risk) 
cohort at 5 years was 2·7 (95% CI 1·5–4·8; p=0·0024; 
AUC 0·57 [95% CI 0·52–0·61]). Percentage of genome 
alteration stratiﬁ es patients at risk of rapid failure 
consistent with occult metastases, and was increased in 
Type IGRT 
rank
MSKCC 
rank
Genes in region*
8p21.3 Del 1 5 PEBP4, RHOBTB2, TNFRSF10B, TNFRSF10C, TNFRSF10D,TNFRSF10A, 
CHMP7, LOXL2, ENTPD4
8p11.22 Del 42 1 FGFR1, C8orf86
8p23.1 Del 2 2 DEFB103A, DEFB103B, SPAG11B, DEFB104A, DEFB104B, DEFB106A, 
DEFB106B, DEFB105A, DEFB105B, DEFB107A, DEFB107B, SPAG11A, 
DEFB4
8p22.1 Del 3 3 NKX3-1, STC1
8q24.3 Amp 29 78 COL22A1 KCNK9 TRAPPC9 CHRAC1 EIF2C2 PTK2 DENND3 SLC45A4 
GPR20 PTP4A3 FLJ43860 TSNARE1 BAI1 ARC JRK PSCA LY6K C8orf55 
SLURP1 LYPD2 LYNX1 LY6D GML
8q21.2 Amp 7 167 REXO1L1
16q22.2 Del 16 9 HP, HPR, TXNL4B, DHX38, PMFBP1, ZFHX3
16q23.2 Del 6 52 WWOX, MAF, DYNLRB2, CDYL2, C16orf61, CENPN, ATMIN, C16orf46, 
GCSH, PKD1L2, BCMO1, GAN, CMIP
6q15 Del 13 17 MAP3K7, BACH2
15q11 Del 16 60 LRCH1 ESD HTR2A SUCLA2 NUDT15 MED4 ITM2B RB1 P2RY5 RCBTB2 
CYSLTR2 FNDC3A MLNR CDADC1 CAB39L SETDB2 PHF11 RCBTB1 
ARL11 EBPL KPNA3 C13orf1 TRIM13 KCNRG
Chromosomal regions assessed for recurrence in the Toronto and MSKCC cohorts. Genes with most copy number 
alterations or those with known or putative cancer associations are shown. IGRT=image-guided radiotherapy. 
MSKCC=Memorial Sloan Kettering Cancer Center. *Genes with most copy number alterations or those with known or 
putative cancer associations.
Table 2: Most recurrently aberrant regions
Figure 1: Kaplan-Meier analysis of biochemical-relapse free survival for 
patients stratiﬁ ed by tumour subtype
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the primary tumours of patients who developed 
metastases compared with in those who did not and had 
a follow-up time of at least 5 years (median 9·2% [IQR 
3·6–13] vs 2·8% [0·33–6·8]; p=0·0043 pooled Toronto 
and MSKCC cohorts, two-sided Mann-Whitney U test; 
appendix pp 52–54).
The median percentage of genome alteration diﬀ ered 
signiﬁ cantly among our genomic subtypes, with subtypes 1 
and 4 having the highest (12% [IQR 8·9–16]) and lowest 
(1·3% [0·16–3·2]) median percentages, respectively 
(appendix p 55). After the addition of percentage of 
genome alteration to the multivariate Cox proportional 
hazard model for subtypes, only subtypes 2 and 3 remained 
prognostic, suggesting that their prognostic ability stems 
from both speciﬁ c genetic aberrations and general 
genomic instability (appendix p 18).
Hypoxia is an important aspect of cancer metabolism 
and in itself can be prognostic in patients with prostate 
cancer.19,20 We used three hypoxia RNA signatures that 
have been validated in other tumour types to estimate 
hypoxia within the pooled radical prostatectomy mRNA 
cohorts (108 MSKCC patients and 110 Cambridge 
patients; table 3 and ﬁ gure 4A–C; appendix p 22).27–29 
None of these signatures were univariately prognostic, 
nor were they related to Gleason score, PSA, T category, 
or percentage of genome alteration (appendix 56–59). 
However, when we separated patients into four groups 
on the basis of high versus low percentage of genome 
alteration and high versus low hypoxia values, we found 
that hypoxia increased the prognostic accuracy of the 
percentage genome alteration for risk of biochemical 
relapse. Patients with a high percentage of alteration and 
high hypoxia have the worst prognosis, whereas those 
with high hypoxia alone (low percentage of alteration) 
responded well after radical prostatectomy (ﬁ gure 4A–C, 
appendix pp 23–24, 60–61).
To validate this ﬁ nding, we used the Toronto cohort 
because the biobanking of frozen biopsies was 
completed with simultaneous and direct assessment of 
tumour hypoxia at the same intraprostatic locale.20 This 
cohort therefore contained direct measurements of 
hypoxia denoted by patient-speciﬁ c values for 
proportion of oxygen measurements less than 
20 mm Hg (HP20; appendix p 25).20 The median HP20 
in our cohort was 81% (range 64–93). Although previous 
ﬁ ndings in a larger cohort have shown that hypoxia was 
independently prognostic of image-guided-radiotherapy 
outcome, our results did not show any signiﬁ cant 
association between median HP20 and increased 
biochemical-free survival (log-rank p=0·13; appendix 
p 62).20 Directly measured HP20 values were not related 
to the clinical covariates, genomic subtype, percentage 
of genome alteration, or with any individual copy 
number alteration, appendix pp 63–65), supporting a 
unique role in tumour biology of prostate cancer. We 
again noted that patients with a low percentage of 
genome alteration and low hypoxia had the best 
outcome (biochemical relapse-free survival at 5 years 
was 93%), whereas those with high levels of both 
measures had the worst (49%; ﬁ gure 4D). Moreover, we 
recorded a statistically signiﬁ cant interaction between 
Figure 2: Genomic instability 
(PGA) as an independent 
prognostic factor in patients 
with prostate cancer 
PGA is not a proxy for Gleason 
grade (A), clinical T category 
(B), or PSA (C; n=336, Toronto 
IGRT, Memorial Sloan 
Kettering Cancer Center, and 
Cambridge low-risk to 
intermediate-risk National 
Comprehensive Cancer 
Network classiﬁ cation risk 
groups combined). p values 
were obtained by two-tailed 
Kruskal-Wallis tests (A) and 
Mann-Whitney tests (B–C). 
Horizontal lines show median 
PGA values per group. 
IGRT=image-guided 
radiotherapy. RP=radical 
prostatectomy.
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percentage of genome alteration and hypoxia 
(unadjusted HR for biochemical relapse 3·8 [95% CI 
1·2–12]; Wald p=0·019; appendix pp 26–27) when used 
as a combined prognostic index. Again, patients whose 
tumour solely showed hypoxia, but not genome 
alteration, fared better than expected for patients with 
hypoxic tumours after image-guided radiotherapy, 
suggesting that cohorts of patients with high hypoxia 
and a high percentage of genome alteration could 
beneﬁ t from treatment intensiﬁ cation.
Because speciﬁ c genes (ﬁ gure 1), general genomic 
instability (ﬁ gures 2, 3), and tumour microenvironment 
(ﬁ gure 4) all play a part in determination of patient 
prognosis, we postulated that a supervised machine 
learning approach would capture the complex and 
unknown interactions between genes underlying these 
events. Using a random forest21 classiﬁ er trained on the 
Toronto cohort, we developed a biopsy-driven prognostic 
signature that predicts biochemical failure and could 
guide clinical decisions before, and independent of, 
treatment (appendix pp 66–67). The resulting 100-loci 
(276 genes) DNA signature was validated in two 
independent cohorts (ﬁ gure 5; appendix 28–30, 68–77). 
We ﬁ rst veriﬁ ed the signature in the independent low-
risk and intermediate-risk MSKCC cohort, in which it 
predicted biochemical relapse with an area under the 
curve of 0·74 (95% CI 0·65–0·83). This signature is 
more eﬀ ective than clinical variables for prediction of 
biochemical relapse (table 4; appendix pp 28, 68–69). 
58% (95% CI 35–96) of patients in the MSKCC low-risk 
to intermediate-risk groups who were classiﬁ ed as poor 
prognosis were biochemical relapse-free at 5 years, 
compared with 89% (85–96) for those classiﬁ ed as good 
prognosis, and this diﬀ erence remained signiﬁ cant 
after adjustment for clinical covariates (multivariate 
analysis HR for biochemical relapse 6·1 [95% CI 
2·0–19]; Wald p=0·0015; appendix pp 29, 70). 
Importantly, our signature eﬀ ectively identiﬁ ed patients 
at risk of relapse within 18 months in the full MSKCC 
cohort, despite not including any high-risk patients in 
the initial training cohort (3·3 [1·1–10]; Wald p=0·038). 
We validated this early-failure eﬀ ect in a second 
independent Cambridge cohort (2·8 [1·7–9·4]; Wald 
p=0·050; appendix pp 30, 70). The HR for the combined 
cohort is 2·9 (95% CI 1·4–6·0; p=0·039; AUC 0·68 
[95% CI 0·63–0·73]). The signature is independent of 
clinical covariates and might identify candidates for 
both treatment intensiﬁ cation and de-intensiﬁ cation 
protocols because it can identify patients with a Gleason 
score 7 who will have biochemical relapse within 
18 months (HR for relapse 2·8 [95% CI 1·2–6·7]; 
Figure 3: Kaplan-Meier analysis of PGA as a prognostic factor for biochemical treatment failure in image-guided radiotherapy patients (A) and those undergoing radical prostatectomy in the 
low-risk and intermediate-risk group (B) and the full group (C)
PGA=percentage of genome alteration. HR=hazard ratio.
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p=0·021) and was highly prognostic for low-risk patients 
(AUC 0·97 [95% CI 0·82–1·0]; appendix pp 71–75). 
Importantly, the signature also identiﬁ ed patients who 
go on to develop metastasis (AUC 0·78 [95% CI 
0·63–0·93]; appendix p 76).
To underpin the potential use of our DNA signature, 
we noted that the signature had AUC and C-index 
values that were greater than 97% (970 000/1 000 000) 
of the empirical null distribution from randomly 
sampled genesets (appendix p 77). Furthermore, our 
signature outperformed 23 previously published RNA 
signatures for prostate cancer biochemical relapse-free 
survival rates after training of random forests with a 
cohort of 1299 low-risk to high-risk patients with 
prostate cancer (including 293 low-risk to intermediate-
risk patients) with mRNA microarray data (ﬁ gure 6). 
Application of these trained forests to the 108 MSKCC 
patients with information about both mRNA and 
copy number alteration showed that our DNA 
signature has the highest overall AUC (ﬁ gure 6A, B; 
appendix pp 31, 78).
There is a low alteration rate for most of the genes 
identiﬁ ed in the signature: 154 (56%) of 276 genes had 
copy-number alterations in zero to 39 patients (of a 
total sample size of 397 patients), which is less than 
10% of the total combined cohorts size (appendix p 79). 
Figure 4: Kaplan-Meier analysis of biochemical relapse for patients stratiﬁ ed by PGA and hypoxia values
Combining genome instability (PGA) and hypoxia within the same patient has an additive and independent prognostic eﬀ ect when tumour hypoxia is measured 
with the Buﬀ a (A), West (B), or Winter RNA signatures (C) in the pooled radical prostatectomy full cohorts (n=271). When genomic instability (PGA) and hypoxia 
(HP20) were combined within the same patient, we noted a multiplicative and independent prognostic eﬀ ect in image-guided radiotherapy patients (D). 
HP20=proportion of oxygen measurements less than 20 mm Hg.
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These results strongly support the use of multigene 
models, because our biopsy-based DNA signature 
outperformed reported prognostic genes (appendix 
p 80). Signature regions are distributed across 
14 chromosomes and range by an order of magnitude 
in their importance to prediction accuracy (appendix 
p 81). Notably, genes in these regions relate to lipid 
metabolism (appendix p 82).
We noted that the signature directly accounts for 
genomic instability (appendix pp 82–85). First, patients 
with subtype-4 tumours have signiﬁ cantly lower 
signature risk scores than do those with other subtypes 
(median 0·17 [IQR 0·0026–0·32] vs 0·41 [0·31–0·61]; 
p<0·0001, two-sided Mann-Whitney U test). Second, 
percentage of genome alteration diﬀ ers signiﬁ cantly 
between the classes predicted by the signature and can 
be estimated from the gene signature (Spearman’s 
correlation between whole-genome and signature-
estimated percentage of genome alteration PGA  0·73; 
p<0·0001), thereby providing similar prognostic 
information. Importantly, signature-based estimates of 
percentage of alteration remain highly prognostic, and 
the addition of 30 genes (selected from the Toronto 
cohort) improves estimates of percentage of alteration 
in the validation cohorts (eg, MSKCC: Spearman’s  
0·73 vs 0·87; p<0·0001; appendix p 32). The HR of 
percentage of genome alteration as a continous variable 
estimated from these 306 genes is identical to that of 
the true percentage of genome alteration in the MSKCC 
cohort and nearly identical to that of the Cambridge 
cohort. Taken together, these results show that our 
treatment-independent DNA-prognostic signature 
measures genomic instability in addition to lipid 
metabolism pathways, suggesting our signature might 
identify candidates for treatment-intensiﬁ cation trials 
targetting these processes (appendix pp 86–91).
Discussion
Our ﬁ ndings show that combined indices of genomic 
instability and hypoxia can improve accuracy of prognosis 
in patients with localised prostate cancer in the context of 
present clinicopathological variables. Development of 
prostate-cancer biomarkers to guide disease management 
at the time of diagnosis is a diﬃ  cult but crucial challenge 
in view of the high rates of overtreatment and clinical 
relapse.30 Initial investigation in the Toronto cohort 
showed striking genomic heterogeneity in the pre-
treatment biopsies from these patients, and has impli-
cations for the discovery of driver mutations in prostate 
cancer. No copy number alterations were recurrent in 
more than 47% of patients and the number of alterations 
per patient ranged from zero to 187. We were, however, 
able to identify independent molecular prognostic 
subtypes based on genome-wide copy number alteration 
proﬁ les in the Toronto cohort. 
Inclusion of additional patients from the independent 
MSKCC cohort of low-risk and intermediate-risk patients 
Figure 5: A prognostic DNA signature for prostate cancer
Multivariate Cox proportional hazard model adjusting for clinical covariates 
(Gleason score and pretreatment PSA) in the low-risk and intermediate-risk 
groups (A) and when applied to the full pooled radical prostatectomy cohort 
(n=271) the signature for copy number alteration identiﬁ es patients who will 
fail rapidly (B). HR=hazard ratio. Signature positive=patients whose tumour 
genomics were positive for the 100-loci DNA. Signature negative=patients 
whose tumour genomics were negative for the DNA signature.
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led to larger subtype sizes amenable to analyses of 
biochemical relapse-free survival, showing signiﬁ cant 
diﬀ erences in patient outcome according to subtype. 
Patients ﬂ agged by our copy-number alteration-based 
signature had biochemical relapse rates that were 
increased by up to six times, and were at risk of failure 
within 18 months, all within the clinical context of 
Gleason score, T category, and PSA. In particular, this 
signature is highly eﬀ ective for low-risk patients, because 
it can identify those ineligible for active surveillance and 
provide additional assurance for those who are. For 
instance, if the DNA signature was used by clinicians 
today, of 1000 patients diagnosed with localised disease, 
144 patients would be oﬀ ered more aggressive treatment 
(all signature-positive patients) and 650 would have the 
support for active surveillance instead of local treatment 
(low-risk to intermediate-risk signature-negative 
patients).
Preclinical experimental work supports hypoxia 
generating a mutator phenotype (decreased DNA repair 
leading to increased mutation rate and genomic 
instability) and selecting for genetically unstable clones, 
in addition to an increased capacity for distant 
metastases.18 This metastatic phenotype occurs inde-
pendently of local treatment; hypoxia is associated with 
both local relapse after image-guided radiotherapy and 
biochemical failure and distant metastasis in patients 
receiving image-guided radiotherapy or radical 
prostatectomy for prostate cancer.19,20 Here we have 
shown that simultaneous measurement of tumour 
hypoxia and genomic instability can improve the 
prognostic capability of a pretreatment biopsy by 
combining the independent biology of cancer genomics 
with the tumour microenvironment. Moreover, the poor 
prognosis previously associated with hypoxia19,20 might 
have been related to genomic instability within a subset 
of these specimens, because hypoxia itself was not 
associated with poor prognosis in the absence of a 
heightened percentage of genome alteration.
Cancer-cell metabolism (increased glycolysis, high 
lactate, and hypoxia) is related to oncogene activation and 
loss of tumour suppressor genes, and increased lipid and 
fatty acid synthesis have been associated with progression 
of prostate cancer.31,32 Therefore it is striking that our 
supervised machine-learning approach led to the 
discovery of a genetic signature enriched for genes 
involved in lipid biology. Combined with the ﬁ nding that 
constitutive activation of mTORC1 renders hypoxic cells 
dependent on exogenous desaturated lipids, our 
signature could represent abnormalities in cancer 
metabolism amenable to targeting of lipid synthesis.31–34 
Further more, our signature eﬃ  ciently captures the 
prognostic eﬀ ect of percentage of genome alteration—a 
surrogate for genomic instability. Because androgen 
deprivation therapy improves oxygenation35 and reduces 
DNA repair36 in patients with prostate cancer, we 
speculate that such therapies targeting hypoxia and 
genomic instability might be eﬀ ective in prevention of 
clinical relapse. Patients ﬂ agged by our signature might 
beneﬁ t from patient-speciﬁ c intensiﬁ cation with 
androgen deprivation therapy or other systemic therapies 
Figure 6: Training and comparison of random forest signatures for 
23 previously published RNA signatures for biochemical relapse-free survival
We trained a clinical model (in green) with clinical variables: pretreatment PSA, 
biopsy-based Gleason score, and T category. We compared our DNA-based 
signature (CNA_RF, shown in red) with these signatures in the 108 Memorial 
Sloan Kettering Cancer Center patients with information about both mRNA and 
CNA. The DNA, RNA, and clinical signatures were trained in a cohort of 293 low-
risk to intermediate-risk patients with prostate cancer (A) and 1299 low-risk to 
high-risk patients (B), including some with locally advanced disease. In cases 
where more than one study published more than one signature, only the best 
performing signature is shown. CNA=copy number alterations. AUC=area under 
the receiver operator curve.
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to oﬀ set both local and systemic resistance, independent 
of primary treatment.
To our knowledge, this is the ﬁ rst report of biopsy-
driven, DNA-based indices that predicts prognosis in 
patients who received either image-guided radiotherapy 
or radical prostatectomy as primary therapy for patients 
with prostate cancer (panel). DNA alterations might be 
less variable than RNA abundance patterns within 
intraprostatic biopsies from dynamic tumour micro-
environments, and more stable ex vivo during formalin-
ﬁ xed, paraﬃ  n-embedded protocols. This ﬁ nding 
suggests that our DNA signatures are robust for clinical 
application. Because our training cohort was obtained 
before primary therapy, our study supports the 
characterisation of complex indices, showing a priori 
interpatient heterogeneity, soon after diagnostic MRI-
guided or transurethral ultrasound-guided biopsies. 
Indeed, we have shown that frozen biopsies are 
amenable to whole-genome sequencing to assess 
intrapatient heterogeneity in genomic aberrations 
(Boutros PC, unpublished).
Our study has several caveats. Use of biochemical 
relapse as an endpoint is suboptimum compared with 
prostate cancer-speciﬁ c mortality or time to metastasis. 
Nonetheless, our signature shows promise in 
identiﬁ cation of patients with metastasis, and can identify 
patients who will have biochemical relapse before 
18 months, which has been shown to be predictive for 
prostate cancer-speciﬁ c mortality.6,7 Although the cohorts 
diﬀ er slightly in the distribution of clinicopathological 
factors, these diﬀ erences changed neither treatment nor 
survival, making it very unlikely that the diﬀ erences aﬀ ect 
the interpretation of our results. Nevertheless, we did 
systematically stratify our analyses according to these 
factors when we assessed prognostic markers. A subset of 
patients were given adjuvant treatment; however, we do 
not yet know how adjuvant treatment aﬀ ects the 
performance of our signature. We will explore this 
outcome in new cohorts of patients treated with image-
guided radiotherapy or radical prostatectomy with or 
without androgen deprivation therapy, and assess 
whether the biomarker would become a predictive, rather 
than a solely prognostic, biomarker.
From a technical perspective, despite diﬀ erent 
resolutions between the copy number alteration 
platforms used for each cohort, the copy number 
alteration indices developed in the Toronto cohort 
validated in the radical prostatectomy cohorts. The 
hypoxia probes measure global hypoxia within a prostate-
cancer locale, but do not measure intracellular hypoxia. 
As a result, the DNA is obtained from a large region 
relative to sites of hypoxia. In future studies we will 
characterise the DNA, RNA, and epigenetic proﬁ les of 
foci within patients who receive oral pimonidazole before 
treatment to investigate the genomic–hypoxia prognostic 
association in ﬁ ner detail. Finally, eﬀ orts are underway to 
reduce the signature size without loss of prognostic 
information related to metabolism or genomic instability, 
and to improve the sensitivity of our signature with 
multimodal data sets (eg, combined DNA, RNA and 
epigenetic analyses) emerging from studies from the 
International Cancer Genome Consortium and The 
Cancer Genome Atlas.
Identiﬁ cation of the correct patients to treat while 
avoiding overtreatment in the low-risk to intermediate-
risk group remains an important clinical dilemma. We 
envision the use of genomic instability and 
microenvironment signatures to divert patients from 
present clinical risk categories to novel clinical trials of 
treatment intensiﬁ cation, whereby patients with poor 
prognosis based on these novel biomarkers can be 
enrolled into trials that add combined local and systemic 
therapies. Additionally, low-risk and intermediate-risk 
patients with low levels of hypoxia and and low 
percentages of genome alteration could be entered into 
clinical trials of active surveillance. These precision 
medicine approaches set the stage for novel treatment 
intensiﬁ cation and treatment deintensiﬁ cation trials to 
either increase cure rates by prevention of progression to 
metastatic castration-resistant prostate cancer or to 
reduce the burden of overtreatment.
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Systematic review
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simultaneously.
Interpretation
We propose the use of DNA-based and RNA-based signatures 
to measure genomic instability and tumour hypoxia to guide 
clinical management of patients with primary diagnostic 
biopsies. Our 100-loci DNA signature, which measures 
genomic instability and is enriched for lipid metabolism 
genes, outperforms previously published RNA-based 
prognostic signatures for prostate cancer. Once our assays 
undergo clinical quality assurance protocols within a hospital 
setting, clinicians can use this assay to divert patients to 
appropriate clinical trials.
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